ArticleJournal of medical signals and sensors2025
Isfahan Artificial Intelligence Event 2023: Macular Pathology Detection Competition.
Article in Journal of medical signals and sensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Computer-aided diagnosis (CAD) methods have become of great interest for diagnosing macular diseases over the past few decades. Artificial intelligence (AI)-based CADs offer several benefits, including speed, objectivity, and thoroughness. They are utilized as an assistance system in various ways, such as highlighting relevant disease indicators to doctors, providing diagnosis suggestions, and presenting similar past cases for comparison. Methods: Much specifically, retinal AI-CADs have been developed to assist ophthalmologists in analyzing optical coherence tomography (OCT) images and making retinal diagnostics simpler and more accurate than before. Retinal AI-CAD technology could provide a new insight for the health care of humans who do not have access to a specialist doctor. AI-based classification methods are critical tools in developing improved retinal AI-CAD technology. The Isfahan AI-2023 challenge has organized a competition to provide objective formal evaluations of alternative tools in this area. In this study, we describe the challenge and those methods that had the most successful algorithms. Results: A dataset of OCT images, acquired from normal subjects, patients with diabetic macular edema, and patients with other macular disorders, was provided in a documented format. The dataset, including the labeled training set and unlabeled test set, was made accessible to the participants. The aim of this challenge was to maximize the performance measures for the test labels. Researchers tested their algorithms and competed for the best classification results. Conclusions: The competition is organized to evaluate the current AI-based classification methods in macular pathology detection. We received several submissions to our posted datasets that indicate the growing interest in AI-CAD technology. The results demonstrated that deep learning-based methods can learn essential features of pathologic images, but much care has to be taken in choosing and adapting appropriate models for imbalanced small datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.